Intraoperative assessment of tumor resection margins in breast-conserving surgery using 18F-FDG cerenkov luminescence imaging: A first-in-human feasibility study

Maarten R. Grootendorst, Massimiliano Cariati, Sarah E. Pinder, Ashutosh Kothari, Michael Douek, T. Kovács, Hisham Hamed, Amit Pawa, Fiona Nimmo, Julie Owen, Vernie Ramalingam, Sweta Sethi, Sanjay Mistry, Kunal Vyas, David S. Tuch, Alan Britten, Mieke Van Hemelrijck, Gary J. Cook, Chris Sibley-Allen, Sarah AllenArnie Purushotham

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

In early-stage breast cancer, the primary treatment option for most women is breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess resection margins intraoperatively, because on average 20% of patients require further surgery to achieve clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by 18F-FDG. Its high-resolution and small size imaging equipment make CLI a promising technology for intraoperative margin assessment. A first-in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative assessment of tumor margins in BCS. Methods: Twenty-two patients with invasive breast cancer received 18F-FDG (5 MBq/kg) 45-60 min before surgery. Sentinel lymph node biopsy was performed using an increased 99mTc-nanocolloid activity of 150 MBq to facilitate nodal detection against the g-probe background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 2 lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an investigational CLI system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 patients were included in the analysis dataset. Cerenkov luminescence images from incised BCS specimens were analyzed postoperatively by 2 surgeons blinded to the histopathology results, and mean radiance and margin distance were measured. The agreement between margin distance on CLI and histopathology was assessed. Radiation doses to staff were measured. Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-background ratio were 560 6 160 photons/s/cm2/sr and 2.41 6 0.54, respectively. All 15 assessable margins were clear on CLI and histopathology. The agreement in margin distance and interrater agreement was good (k 5 0.81 and 0.912, respectively). Sentinel lymph nodes were successfully detected in all patients. The radiation dose to staff was low; surgeons received a mean dose of 34 6 15 mSv per procedure. Conclusion: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumor margins in BCS. A randomized controlled trial will evaluate the impact of this technique on reexcision rates.

Original languageEnglish
Pages (from-to)891-898
Number of pages8
JournalJournal of Nuclear Medicine
Volume58
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Segmental Mastectomy
Fluorodeoxyglucose F18
Feasibility Studies
Luminescence
Neoplasms
Radiation
Breast Neoplasms
Margins of Excision
Sentinel Lymph Node Biopsy
Molecular Imaging
Optical Imaging
Photons
Randomized Controlled Trials
Technology
Light
Equipment and Supplies

Keywords

  • F-FDG
  • Breast-conserving surgery
  • Cerenkov luminescence imaging
  • Sentinel lymph node biopsy
  • Tumor margins

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Intraoperative assessment of tumor resection margins in breast-conserving surgery using 18F-FDG cerenkov luminescence imaging : A first-in-human feasibility study. / Grootendorst, Maarten R.; Cariati, Massimiliano; Pinder, Sarah E.; Kothari, Ashutosh; Douek, Michael; Kovács, T.; Hamed, Hisham; Pawa, Amit; Nimmo, Fiona; Owen, Julie; Ramalingam, Vernie; Sethi, Sweta; Mistry, Sanjay; Vyas, Kunal; Tuch, David S.; Britten, Alan; Van Hemelrijck, Mieke; Cook, Gary J.; Sibley-Allen, Chris; Allen, Sarah; Purushotham, Arnie.

In: Journal of Nuclear Medicine, Vol. 58, No. 6, 01.06.2017, p. 891-898.

Research output: Contribution to journalArticle

Grootendorst, MR, Cariati, M, Pinder, SE, Kothari, A, Douek, M, Kovács, T, Hamed, H, Pawa, A, Nimmo, F, Owen, J, Ramalingam, V, Sethi, S, Mistry, S, Vyas, K, Tuch, DS, Britten, A, Van Hemelrijck, M, Cook, GJ, Sibley-Allen, C, Allen, S & Purushotham, A 2017, 'Intraoperative assessment of tumor resection margins in breast-conserving surgery using 18F-FDG cerenkov luminescence imaging: A first-in-human feasibility study', Journal of Nuclear Medicine, vol. 58, no. 6, pp. 891-898. https://doi.org/10.2967/jnumed.116.181032
Grootendorst, Maarten R. ; Cariati, Massimiliano ; Pinder, Sarah E. ; Kothari, Ashutosh ; Douek, Michael ; Kovács, T. ; Hamed, Hisham ; Pawa, Amit ; Nimmo, Fiona ; Owen, Julie ; Ramalingam, Vernie ; Sethi, Sweta ; Mistry, Sanjay ; Vyas, Kunal ; Tuch, David S. ; Britten, Alan ; Van Hemelrijck, Mieke ; Cook, Gary J. ; Sibley-Allen, Chris ; Allen, Sarah ; Purushotham, Arnie. / Intraoperative assessment of tumor resection margins in breast-conserving surgery using 18F-FDG cerenkov luminescence imaging : A first-in-human feasibility study. In: Journal of Nuclear Medicine. 2017 ; Vol. 58, No. 6. pp. 891-898.
@article{1f1bbce815994194a10911aa39995228,
title = "Intraoperative assessment of tumor resection margins in breast-conserving surgery using 18F-FDG cerenkov luminescence imaging: A first-in-human feasibility study",
abstract = "In early-stage breast cancer, the primary treatment option for most women is breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess resection margins intraoperatively, because on average 20{\%} of patients require further surgery to achieve clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by 18F-FDG. Its high-resolution and small size imaging equipment make CLI a promising technology for intraoperative margin assessment. A first-in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative assessment of tumor margins in BCS. Methods: Twenty-two patients with invasive breast cancer received 18F-FDG (5 MBq/kg) 45-60 min before surgery. Sentinel lymph node biopsy was performed using an increased 99mTc-nanocolloid activity of 150 MBq to facilitate nodal detection against the g-probe background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 2 lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an investigational CLI system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 patients were included in the analysis dataset. Cerenkov luminescence images from incised BCS specimens were analyzed postoperatively by 2 surgeons blinded to the histopathology results, and mean radiance and margin distance were measured. The agreement between margin distance on CLI and histopathology was assessed. Radiation doses to staff were measured. Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-background ratio were 560 6 160 photons/s/cm2/sr and 2.41 6 0.54, respectively. All 15 assessable margins were clear on CLI and histopathology. The agreement in margin distance and interrater agreement was good (k 5 0.81 and 0.912, respectively). Sentinel lymph nodes were successfully detected in all patients. The radiation dose to staff was low; surgeons received a mean dose of 34 6 15 mSv per procedure. Conclusion: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumor margins in BCS. A randomized controlled trial will evaluate the impact of this technique on reexcision rates.",
keywords = "F-FDG, Breast-conserving surgery, Cerenkov luminescence imaging, Sentinel lymph node biopsy, Tumor margins",
author = "Grootendorst, {Maarten R.} and Massimiliano Cariati and Pinder, {Sarah E.} and Ashutosh Kothari and Michael Douek and T. Kov{\'a}cs and Hisham Hamed and Amit Pawa and Fiona Nimmo and Julie Owen and Vernie Ramalingam and Sweta Sethi and Sanjay Mistry and Kunal Vyas and Tuch, {David S.} and Alan Britten and {Van Hemelrijck}, Mieke and Cook, {Gary J.} and Chris Sibley-Allen and Sarah Allen and Arnie Purushotham",
year = "2017",
month = "6",
day = "1",
doi = "10.2967/jnumed.116.181032",
language = "English",
volume = "58",
pages = "891--898",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - Intraoperative assessment of tumor resection margins in breast-conserving surgery using 18F-FDG cerenkov luminescence imaging

T2 - A first-in-human feasibility study

AU - Grootendorst, Maarten R.

AU - Cariati, Massimiliano

AU - Pinder, Sarah E.

AU - Kothari, Ashutosh

AU - Douek, Michael

AU - Kovács, T.

AU - Hamed, Hisham

AU - Pawa, Amit

AU - Nimmo, Fiona

AU - Owen, Julie

AU - Ramalingam, Vernie

AU - Sethi, Sweta

AU - Mistry, Sanjay

AU - Vyas, Kunal

AU - Tuch, David S.

AU - Britten, Alan

AU - Van Hemelrijck, Mieke

AU - Cook, Gary J.

AU - Sibley-Allen, Chris

AU - Allen, Sarah

AU - Purushotham, Arnie

PY - 2017/6/1

Y1 - 2017/6/1

N2 - In early-stage breast cancer, the primary treatment option for most women is breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess resection margins intraoperatively, because on average 20% of patients require further surgery to achieve clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by 18F-FDG. Its high-resolution and small size imaging equipment make CLI a promising technology for intraoperative margin assessment. A first-in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative assessment of tumor margins in BCS. Methods: Twenty-two patients with invasive breast cancer received 18F-FDG (5 MBq/kg) 45-60 min before surgery. Sentinel lymph node biopsy was performed using an increased 99mTc-nanocolloid activity of 150 MBq to facilitate nodal detection against the g-probe background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 2 lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an investigational CLI system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 patients were included in the analysis dataset. Cerenkov luminescence images from incised BCS specimens were analyzed postoperatively by 2 surgeons blinded to the histopathology results, and mean radiance and margin distance were measured. The agreement between margin distance on CLI and histopathology was assessed. Radiation doses to staff were measured. Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-background ratio were 560 6 160 photons/s/cm2/sr and 2.41 6 0.54, respectively. All 15 assessable margins were clear on CLI and histopathology. The agreement in margin distance and interrater agreement was good (k 5 0.81 and 0.912, respectively). Sentinel lymph nodes were successfully detected in all patients. The radiation dose to staff was low; surgeons received a mean dose of 34 6 15 mSv per procedure. Conclusion: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumor margins in BCS. A randomized controlled trial will evaluate the impact of this technique on reexcision rates.

AB - In early-stage breast cancer, the primary treatment option for most women is breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess resection margins intraoperatively, because on average 20% of patients require further surgery to achieve clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by detecting light emitted by 18F-FDG. Its high-resolution and small size imaging equipment make CLI a promising technology for intraoperative margin assessment. A first-in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative assessment of tumor margins in BCS. Methods: Twenty-two patients with invasive breast cancer received 18F-FDG (5 MBq/kg) 45-60 min before surgery. Sentinel lymph node biopsy was performed using an increased 99mTc-nanocolloid activity of 150 MBq to facilitate nodal detection against the g-probe background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 2 lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an investigational CLI system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 patients were included in the analysis dataset. Cerenkov luminescence images from incised BCS specimens were analyzed postoperatively by 2 surgeons blinded to the histopathology results, and mean radiance and margin distance were measured. The agreement between margin distance on CLI and histopathology was assessed. Radiation doses to staff were measured. Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-background ratio were 560 6 160 photons/s/cm2/sr and 2.41 6 0.54, respectively. All 15 assessable margins were clear on CLI and histopathology. The agreement in margin distance and interrater agreement was good (k 5 0.81 and 0.912, respectively). Sentinel lymph nodes were successfully detected in all patients. The radiation dose to staff was low; surgeons received a mean dose of 34 6 15 mSv per procedure. Conclusion: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative assessment of tumor margins in BCS. A randomized controlled trial will evaluate the impact of this technique on reexcision rates.

KW - F-FDG

KW - Breast-conserving surgery

KW - Cerenkov luminescence imaging

KW - Sentinel lymph node biopsy

KW - Tumor margins

UR - http://www.scopus.com/inward/record.url?scp=85020171840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020171840&partnerID=8YFLogxK

U2 - 10.2967/jnumed.116.181032

DO - 10.2967/jnumed.116.181032

M3 - Article

C2 - 27932562

AN - SCOPUS:85020171840

VL - 58

SP - 891

EP - 898

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -